RPG Life Sciences Limited has informed the Exchange about Investor Presentation
October 17, 2025
To,
The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.
BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.
Symbol: RPGLIFE
Scrip code: 532983
Dear Sirs,
Sub: Investor Presentation - Financial Results
Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial
Results of the Company for the quarter and half year ended September 30, 2025.
Kindly take the above on record.
Thanking you,
Yours faithfully, For RPG Life Sciences Limited
Rajesh Shirambekar Head – Legal & Company Secretary
Encl: as above
FY26: H1 Performance RPG Life Sciences
Investors’ Presentation
Disclaimer
This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.
The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.
This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.
2
RPG Group: Powered by Passion, Driven by Ethics
RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea. The Group grew in size and strength with several acquisitions in the 1980s and 1990s. RPG Group is one of India’s fastest growing conglomerates with 31,000+ employees, presence in 135+ countries and annual gross revenues of USD 5.2 Bn
EPC major in infrastructure segments like T&D, Civil, Transportation, Oil & Gas, Renewables & Cables
One of India’s leading tyre manufacturers
Global technology consulting and IT services company
Integrated pharma company in formulations and synthetic APIs
Technology solutions company catering to energy and infrastructure
One of India’s largest plantation companies producing tea, rubber, etc.
RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.
Domestic Formulations (DF)
Develop, manufacture and market branded formulations in India & Nepal
Domestic Domestic Formulations Formulations (DF) (DF) 65% 71%
International Formulations (IF)
Develop, manufacture and market oral solid dosage formulations in the generics and branded generics space
APIs 10%
Domestic International Formulations Formulations 66% (IF) 19%
APIs
Develop, manufacture and sell high value synthetic APIs in the general therapeutic category
Leader in Immunosuppressants
9 Therapies represented by High Equity Brands
50+ Markets Presence
3 Manufacturing Facilities
1300+ Employees
RPG Life Sciences: Strong Product Portfolio, Textbook brands; focus on chronic & specialty therapies
Key Therapies
Nephrology
Rheumatology
Oncology
Pain Management
Gastroenterology
Neuropsychiatry
Cardio- Diabeto
Urology
Legacy Portfolio
Immunosuppressants
Textbook Brands
Azathioprine
Azathioprine
Spironolactone
Mycophenolate Mofetil
Diphenoxylate HCl
Cyclosporine
Tacrolimus
Naproxen
Haloperidol
Life Cycle Management (Existing Products)
DF Key Products
New Portfolio
Specialty
Chronic
Trastuzumab
Adalimumab
Bevacizumab
Rituximab
Tofacitinib
Sacubitril+ Valsartan
Vildagliptin
Teneligliptin
Dapagliflozin
Solifenacin
Disopyramide Phosphate
Ferric Carboxymaltose
Denosumab
IF Key Products Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline and so on Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope and so on
APIs Key Products Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole and so on
Business Operations
6
Building a Strong-Consistent-Profitable Business
1
2
3
4
Business Transformation
Focusing on Execution
Building Competitiveness
Energizing Happy Teams
6
>10
3-4x
88%
Bold Moves
High Impact Projects
Share of voice
Happiness Score
1
Business Transformation
Bold Move 1
Galvanizing Organization to an “Inspiring Purpose”: Framing and embedding in the organisation
Bold Move 2
“Small Brands” to Building “Mega Brand of 100 cr +; future 500 cr OTC”: Naprosyn
Bold Move 3
“Small Product” to Building “Mega Rx Portfolio of 100 cr +; Potential 200 cr” : Immunosuppressants
Bold Move 4
“Small API” segment to Building “Formidable API Business”: Manthan
Bold Move 5
Predominant “Domestic Play” to “Expanded Global Play” : Capex infusion ~140 cr
Bold Move 6
“Operations” Focus to “Sustainable Operations” Focus: ESG
2
Focusing on Execution
Multiple Projects targeted to transform business: ↓ Costs, ↑ Quality, ↑ New Business
1
Comprehensive Business Transformation Project
6
Innovation Projects
2
Plants Infra Modernization-Capacity Expansion Projects
7
Digitalization Projects
3
COGS Reduction Projects
8
M&A Projects
4
Product Re-engineering Projects
9
Med-tech Projects
5
Quality Enhancement Projects
10
ESG Projects
Project Charters, Workstreams, Scope, Review, KPIs Measurement
3
Building Competitiveness :3-4x SOV; Product Re-engineering; Profitable new therapies entry
RPG Serv: ↑ Customer Coverage, ↑ SoV, ↑Engagement
Smart Life cycle Management
Brands
New Combination
New Indication
New Patient Segment
New Dosage form
New Strength
New Customer/ Geography
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
Current doctor reach of 1 Lakh+ doctors pan-India
10
4
Energizing Happy Teams: Happiness Framework People Initiatives for building a happy performance focussed culture
I Cherish our Culture
RPGLS Parivar Tyohar-Utsav Shrankhla Digital RPGLS family get- together
I Live a Purposeful & Balanced life
RPGLS Values Champions Living organizational values
I Love My Work
RPGLS Heroes Outperformance recognition
High Happiness Quotient
I Feel Connected
RPGLS Happiness Forums Leadership Connect – Month & Quarter
I am Growing
We Skill. You Grow. Competency building continuum
Akanksha Career development
I Feel Valued
You Excel. We Applaud. Motivation continuum
Financial Performance
12
Q2 FY26 versus Q1 FY26 Financial Performance
Revenue from Operations
+7.6%
168.9
181.7
Q1 FY26
Q2 FY26
EBITDA & EBITDA Margin
+7.1%
(All figures in Rs. Crores) Figures in circle are Margins
40.7
24.1%
Q1 FY26
43.6
24.0%
17.5%
Q2 FY26
PBT & PBT Margin (excluding exceptional items)
PAT & PAT Margin (excluding exceptional items)
+7.9%
38.2
35.4
21.0%
21.0%
+8.1%
28.5
26.3
15.6%
15.7%
Q1 FY26
Q2 FY26
Q1 FY26
Q2 FY26
Q2 FY26 versus Q2 FY25 Financial Performance
Revenue from Operations
5.5%
172.2
181.7
Q2 FY25
Q2 FY26
EBITDA & EBITDA Margin
(All figures in Rs. Crores) Figures in circle are Margins
-9.0%
47.9
27.8%
Q2 FY25
43.6
24.0%
17.5%
Q2 FY26
PBT & PBT Margin (excluding exceptional items)
PAT & PAT Margin (excluding exceptional items)
42.4
24.6%
-9.8%
38.2
21.0%
-9.6%
31.5
28.5
18.3%
15.7%
Q2 FY25
Q2 FY26
Q2 FY25
Q2 FY26
H1 FY26 versus H1 FY25 Financial Performance
Revenue from Operations
3.8%
337.6
350.6
H1 FY25
H1 FY26
EBITDA & EBITDA Margin
(All figures in Rs. Crores) Figures in circle are Margins
-5.6%
89.3
26.5%
H1 FY25
84.3
24.0%
17.5%
H1 FY26
PBT & PBT Margin (excluding exceptional items)
PAT & PAT Margin (excluding exceptional items)
-6.0%
78.4
73.7
23.2%
21.0%
-6.0%
58.3
54.8
17.3%
15.6%
H1 FY25
H1 FY26
H1 FY25
H1 FY26
H1 FY26: Business Segment-wise Performance
Business Segments
Domestic Formulations (DF)
Domestic Formulations contributed 71% to total sales of H1 FY26 • • New products contribution improving consistently on account of new launches in
Continue to deliver market beating growth
specialty & chronic segments Salesforce productivity consistently improving (currently >6.5 lakhs) Business driven by 5 Pillar strategy
• •
APIs 10%
IF 19%
DF 71%
International Formulations (IF)
International Formulations contributed 19% to total sales of H1 FY26 • New Products/Customers/Markets contribution continues to improve •
Business driven by 4 Pillar strategy
API
API contributed 10% to total sales of H1 FY26 • Growth impacted due to fire incident in one of the manufacturing blocks • •
Continuous thrust on new customer development Business driven by 3 Pillar strategy
16
+13.5%
216.9
246.1
H1 FY25
H1 FY26
+2.1%
65.6
67.0
H1 FY25
H1 FY26
-34.2%
52.3
34.5
H1 FY25
H1 FY26
Key Financial Ratios Yearly Trends (ROCE, ROE, D/E)
ROCE%
29.7%
28.5%
32.9%
31.6%
24.9%
20.9%
9.7%
ROE%
Debt/Equity Ratio
23.4%24.3%
0.22
20.1%22.0%
18.5%
16.4%
FY19
FY20
FY21
FY22
FY23
FY24 FY25 *
FY19 FY20 FY21 FY22 FY23 FY24 FY25 *
FY19
FY20
FY21
FY22
FY23
FY24
FY25
6.7%
0.06
0.01
0.00
0.00
0.00
0.00
Company continues to remain Debt-free
*Excluding impact of exceptional items: land assignment/fire; Including exceptional items, ROCE is 44.0%, ROE is 34.5%
17
RPG Life Sciences ICRA Rating Reaffirmation in FY25 A- (FY19) to A(FY21) to A+ (FY24)
Improvements recorded in ICRA Rating
Factors affecting rating affirmation
• Long term rating
reaffirmed at A+ and outlook retained as stable
• Short term rating reaffirmed at A1
• A robust capital structure and strong debt servicing indicators
based on
o Healthy cash flows o Company continues to remain debt-free o No debt-funded capital expenditure (capex)
•
•
•
Steady growth in Top-line and improving operating margins
Strong brands in the Indian Pharmaceutical Industry
Expansion of product portfolio and geographical presence augur well for growth prospects
Business Strategy
19
Domestic Formulations (DF) Business: Overview & Strategy
Business Overview
Leading Textbook Brands Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace
Diverse Portfolio Operating across mass, mass- specialty, and specialty segments.
Innovation & Growth New launches in biosimilars, chronic, and specialty segments.
Specialist Reach Strong coverage among top specialists: cardiologists, diabetologists, urologists, nephrologists, rheumatologists, oncologists.
Business Strategy
1
Product Portfolio Rejuvenation: Building chronic and specialty portfolios with new launches.
5 Pillars of profitable domestic business growth
2
Strategic Brand Asset Building: Life cycle management through new line extensions, customer segments, & disease segments.
3
4
Customer Coverage Deepening: Expanding field force & deploying digital solutions in targeted therapies.
Sales Force Effectiveness Augmentation: Enhancing competencies and productivity through targeted initiatives.
5
Profitability Improvement: Controlling operating expenses, optimizing manufacturing operations, maintaining sales hygiene, & focusing on a profitable product mix.
International Formulations (IF) Business: Overview & Strategy
Business Overview
Global Reach Presence in regulated and emerging markets across Canada, UK, Germany, France, Australia, SE Asia, and Africa.
Specialist Leadership Strong position in immunosuppressants, with Azathioprine as a flagship product.
Trusted Partnerships Impeccable supply track record and enduring relationships with leading global generic players.
Quality & Expansion Preferred partner for high-quality, process-oriented manufacturing; ongoing investments in plant upgrades and capacity expansion.
Business Strategy
3 pillars of step-wise Global business build up
1
Build Immunosuppressant Portfolio: Expand leadership in immunosuppressants, anchored by flagship products like Azathioprine.
2 Focus on Products with Competitive Advantage: Prioritize products requiring special manufacturing conditions (e.g., low RH/temperature), complex generics, and those with low competition.
3
Expand Footprint in Emerging and Select Markets: Grow presence in markets such as Myanmar, Vietnam, Philippines, Sri Lanka, Egypt, Sudan, Thailand, and South Africa.
APIs Business: Overview & Strategy
Business Overview
Niche API Focus High-value, low-volume APIs and mature, stable molecules.
Global Presence Presence across key geographies: LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India, and more.
Strategic Integration Backward integration with International Formulations, strengthening supply chain resilience.
Trusted Partnerships Enduring relationships with major pharma and leading generic companies.
Business Strategy
1
Market & Customer Expansion: Grow reach for existing products in new and established markets.
3 Pillars of Strategic Growth
2
Niche Product Pipeline: Develop immunosuppressants, limited competition products, and support backward integration for IF/DF.
3
State-of-the-Art Manufacturing: Operate EU/TGA-approved plant with enhanced capacity for quality and compliance.
Infrastructure Capabilities & ESG Initiatives
23
Manufacturing Facilities
Formulations Unit 1, Ankleshwar
Formulations Unit 2, Ankleshwar
API Unit, Navi Mumbai
F1 unit caters to the domestic and emerging markets
• • Multipurpose plant with dedicated product lines for oral dosage forms including tablets,
liquids and powder
• WHO, Kenya, Nigeria approved • Modernization and capacity expansion underway
F2 unit caters to the regulated markets
• • Dedicated product lines for oral dosage (capsules & tablets) • • WHO, EUGMP (from Hamburg Health authority), Canada, Ethiopia, Kenya, Sudan, Nigeria
Equipped to handle low RH and low temperature conditions products
approved
• Modernization and capacity expansion underway
• MF2: Dedicated immunosuppressant facility for regulated and emerging markets including India • MF3: Multipurpose unit catering to regulated and emerging markets including India • MF4: Multipurpose unit catering to emerging markets including India • WHO, TGA Australia approved & Written Confirmation (WC) received from CDSCO • Approved by WHO GMP from Food and Drug Control Administration (FDCA) – Maharashtra, TGA
(Australia), PMDA (Japan)
• Modernization and capacity expansion underway
24
Digital Initiatives: Manufacturing and Quality
Digital Retina Scanner
• Biometric Access with IRIS/ Retina Scanner enables consistency of electronic records and signatures
• Access to only
qualified professionals, Batch Management, Recipe Management, Audit logs
Intelligent Chilling Plant Manager
IOT based AHU monitoring system
Power Management System
• Implementation of Utility Asset Management Systems with access over IoT, supported by Customized Algorithms for Efficient Monitoring, Control & Analytics
• Operates Pumps
•
& Chillers according to Operating Hours to maintain equal run time
• Automatically change over Working pump to Standby if Pump fails during operation
Safe, reliable, efficient, and compliant operation of electrical distribution systems, and connected assets enabling at all times
e-QMS: Digital platform to track all 6 quality parameters
e-DMS: Digital platform to manage manufacturing/quality documents
e-LMS: Digital platform to track training sessions on CGMP
Quality Functions
ESG FY25 update
Initiatives
• Carbon emission reduction
• Energy Efficiency: Pumps; Chillers/Brine Plant; Leakages
rectification
FY25
↓ FY24 : 26.8% ; FY25: 41.2 %
↑ FY24: 26% ; FY25 : 41.0 %
• Water Management: Recycling of STP water; Rainwater
↓ FY 24: 6% ; FY25 : 7.0 %
harvesting
• Waste Management: No landfill waste generation
↓ FY24: 49% ; FY25 : 52.0 %
• Product Responsibility- Adherence to stipulated mandates • Diversity- women deployment, occupational health • Tree Plantation • Employee Well-being: Comorbidity tracking
Strict Quality vigil through Manthan 3 Project
↑ to 6.3% from 4.8%
100+ trees planted
Done for all factory employees
• Data Integrity: Digital initiatives e.g. e-QMS, e-DMS, e-LMS
Implemented at Ankleshwar; Navi Mumbai
• Cybersecurity: IT assets security through EDR tool
Implemented
• Best Practices/Systems and Processes across functions
Sales & Marketing
l
a t n e m n o r i v n E
l
a
i c o S
e c n a n r e v o 26 G
Journey Ahead
27
RPGLS Journey Ahead: 7 strategic pillars of action
1
2
3
4
5
6
7
Portfolio development and mega-brands building
• Project underway to grow our immunosuppressant portfolio to 200+ crores • Focused initiatives to grow Naprosyn to a 100+ crores brand; building our MABs portfolio
Growing our API business
• Focus on new geographies, new launch pipeline and enhancing manufacturing productivity • Focus on strengthening customer relationships and onboarding new high-value customers
Strong Digital Roadmap
• Multiple digital initiatives designed to streamline front-end and backend operations • Initiatives focus on improving efficiency & compliance, reducing costs and growing topline
Mergers & Acquisitions
• M&A Framework with criteria defined - target therapies, brands • Evaluation of multiple proposals underway to identify opportunities for growth synergy
New products across segments, new therapies
• Focused new product pipeline; lab modernization and org expansion complete • Strategy to evaluate and expand into adjacencies in RPGLS strength therapies
State-of-art capacity plants
• 140 crores capex infused since FY22 helped build modern plant with EU, TGA, PMDA, etc. approval • Evaluation ongoing of varied opportunities for improving manufacturing productivity
Talent Development /Acquisition
• Org structure review & role/skill-gaps identification for strengthening • Talent development and talent acquisition across all key business and support functions
T H A N K
Y O U